HER2 Support Group Forums - View Single Post - TDM-1 results reported @ ASCO annual mtg 2012 now in New England Journal of Medicine

Rolepaul · 11-08-2012, 06:35 AM

Roche has been granted a priority review of its Herceptin successor, known as T-DM1. The action date for this review by the U.S. FDA is February 26th, 2013. A spokesperson for Roche has expressed their belief that this priority review increases the likelihood of a market release in early 2013.

This would hopefully mean that a lot more women would get treated. The company is very hopeful.

11-08-2012, 06:35 AM	#15
Rolepaul Senior Member Join Date: Jan 2012 Location: Boulder Colorado as of January 2013 Posts: 391	Re: TDM-1 results reported @ ASCO annual mtg 2012 now in New England Journal of Medic Roche has been granted a priority review of its Herceptin successor, known as T-DM1. The action date for this review by the U.S. FDA is February 26th, 2013. A spokesperson for Roche has expressed their belief that this priority review increases the likelihood of a market release in early 2013. This would hopefully mean that a lot more women would get treated. The company is very hopeful.